Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Toposar Generic Name & Formulations
Legal Class
Rx
General Description
Etoposide 20mg/mL; soln for IV infusion; contains dehydrated alcohol 33.2%, polysorbate 80.
Pharmacological Class
Topoisomerase inhibitor.
How Supplied
Multi-dose vials (5mL, 25mL, 50mL)—1
Manufacturer
Toposar Indications
Indications
Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy.
Toposar Dosage and Administration
Adult
Give by slow IV infusion over 30–60mins. Range 50–100mg/m2 per day on days 1 through 5 to 100mg/m2 per day on days 1, 3, and 5. Repeat course every 3 to 4 weeks after recovery from any toxicity. Renal impairment (CrCl 15–50mL/min): reduce dose to 75%; (CrCl <15mL/min): see literature. Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.
Children
Not established.
Toposar Contraindications
Not Applicable
Toposar Boxed Warnings
Boxed Warning
Should be administered under the supervision of an experienced physician in cancer chemotherapy. Severe myelosuppression.
Toposar Warnings/Precautions
Warnings/Precautions
Monitor for myelosuppression; obtain CBCs with differential, platelets, hemoglobin at baseline, prior to each subsequent dose, during and after therapy. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Renal impairment. Hypoalbuminemia. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Toposar Pharmacokinetics
See Literature
Toposar Interactions
Interactions
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.
Toposar Adverse Reactions
Adverse Reactions
Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, anorexia, mucositis, myelosuppression (esp neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; others.
Toposar Clinical Trials
See Literature
Toposar Note
Not Applicable
Toposar Patient Counseling
See Literature
Toposar Generic Name & Formulations
Legal Class
Rx
General Description
Etoposide 20mg/mL; soln for IV infusion; contains dehydrated alcohol 33.2%, polysorbate 80.
Pharmacological Class
Topoisomerase inhibitor.
How Supplied
Multi-dose vials (5mL, 25mL, 50mL)—1
Manufacturer
Toposar Indications
Indications
First-line treatment of small cell lung cancer.
Toposar Dosage and Administration
Adult
Give by slow IV infusion over 30–60mins. Range 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery from any toxicity. Renal impairment (CrCl 15–50mL/min): reduce dose to 75%; (CrCl <15mL/min): see literature. Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.
Children
Not established.
Toposar Contraindications
Not Applicable
Toposar Boxed Warnings
Boxed Warning
Should be administered under the supervision of an experienced physician in cancer chemotherapy. Severe myelosuppression.
Toposar Warnings/Precautions
Warnings/Precautions
Monitor for myelosuppression; obtain CBCs with differential, platelets, hemoglobin at baseline, prior to each subsequent dose, during and after therapy. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Renal impairment. Hypoalbuminemia. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Toposar Pharmacokinetics
See Literature
Toposar Interactions
Interactions
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.
Toposar Adverse Reactions
Adverse Reactions
Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, anorexia, mucositis, myelosuppression (esp neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; others.
Toposar Clinical Trials
See Literature
Toposar Note
Not Applicable
Toposar Patient Counseling
See Literature
